Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the long term safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney organ transplant

• Phase: Phase 3

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria

• Patients who completed the 12 month core study

• Patients who gave written informed consent to participate in the study Exclusion Criteria

• Not applicable Other protocol-defined exclusion criteria may apply